IT 603

Drug Profile

IT 603

Alternative Names: IT-603

Latest Information Update: 10 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImmuneTarget
  • Class Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Graft-versus-host disease; Transplant rejection

Most Recent Events

  • 10 Aug 2016 IT 603 is available for licensing as of 10 Aug 2016. http://www.immunetarget.com/
  • 10 Aug 2016 Preclinical trials in Graft-versus-host disease in USA (unspecified route)
  • 10 Aug 2016 Preclinical trials in Transplant rejection (Prevention) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top